Novo Nordisk's dramatic share price decline of around 20 percent due to disappointing results for its weight-loss drug Cagrisema affected the Danish krone's stability.
Sren Kristensen highlighted that the large import and export surplus in Denmark creates high demand for the krone, which is influenced significantly by Novo Nordisk's market performance.
Kristensen noted that while the krone has shifted to the weaker side of the euro, the National Bank is not yet concerned unless the decline continues.
He concluded by emphasizing the profound impact Novo Nordisk has on the Danish economy, acknowledging that continuous declines might prompt the National Bank to intervene.
Collection
[
|
...
]